5 Results for "

Pacritinib

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Pacritinib" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-16379
CAS No.: 937272-79-2
Synonyms: SB1518
Target:  

JAK FLT3 STAT ERK Akt Apoptosis

Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis .
loading...
    loading...
20
20 Publications Verification
Cat. No.: HY-16379B
CAS No.: 1228923-42-9
Synonyms: SB1518 citrate
Target:  

JAK FLT3 STAT ERK Akt Apoptosis

Research Areas:  

Metabolic Disease Cancer

Pacritinib citrate (SB1518 citrate) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib citrate inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib citrate normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib citrate can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis .
loading...
    loading...
Cat. No.: HY-16379S
Synonyms: SB1518-d4
Pacritinib-d4 (SB1518-d4) is the deuterated-labeled Pacritinib (HY-16379). Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis .
loading...
    loading...
Cat. No.: HY-16379R
CAS No.: 937272-79-2
Synonyms: SB1518 (Standard)
Pacritinib (Standard) (SB1518 (Standard)) is the analytical standard of Pacritinib (HY-16379). This product is intended for research and analytical applications. Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis .
loading...
    loading...
Cat. No.: HY-16379A
CAS No.: 1228923-43-0
Synonyms: SB1518 hydrochloride
Target:  

JAK FLT3 STAT ERK Akt Apoptosis

Pacritinib hydrochloride (SB1518 hydrochloride) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib hydrochloride inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib hydrochloride normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib hydrochloride can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis .
loading...
    loading...